Pernille Tine Jensen

Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients : A Systematic Literature Review. / European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group.

I: International Journal of Gynecological Cancer, Bind 28, Nr. 4, 05.2018, s. 808-817.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group 2018, 'Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review', International Journal of Gynecological Cancer, bind 28, nr. 4, s. 808-817. https://doi.org/10.1097/IGC.0000000000001211

APA

European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group (2018). Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review. International Journal of Gynecological Cancer, 28(4), 808-817. https://doi.org/10.1097/IGC.0000000000001211

CBE

European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group. 2018. Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review. International Journal of Gynecological Cancer. 28(4):808-817. https://doi.org/10.1097/IGC.0000000000001211

MLA

European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group. "Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review". International Journal of Gynecological Cancer. 2018, 28(4). 808-817. https://doi.org/10.1097/IGC.0000000000001211

Vancouver

European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group. Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review. International Journal of Gynecological Cancer. 2018 maj;28(4):808-817. https://doi.org/10.1097/IGC.0000000000001211

Author

European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group. / Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients : A Systematic Literature Review. I: International Journal of Gynecological Cancer. 2018 ; Bind 28, Nr. 4. s. 808-817.

Bibtex

@article{d0f27af4ec094d74b9776feac7a5c4f2,
title = "Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review",
abstract = "OBJECTIVES: Vulva cancer (VC) treatment carries a high risk of severe late effects that may have a negative impact on quality of life (QoL). Patient-reported outcome measures (PROMs) are increasingly used when evaluating disease- and treatment-specific effects. However, the adequacy of measures used to assess sequelae and QoL in VC remains unclear. The aims of the present study were to evaluate disease- and treatment-related effects as measured by PROMs in VC patients and to identify available VC-specific PROMs.METHODS/MATERIALS: A systematic literature search from 1990 to 2016 was performed. The inclusion criterion was report of disease- and treatment-related effects in VC patients using PROMs in the assessment. Methodological and reporting quality was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. This systematic review was performed as part of phase 1 of the development of a European Organisation for Research and Treatment of Cancer QoL questionnaire for VC patients.RESULTS: The search revealed 2299 relevant hits, with 11 articles extracted including a total of 535 women with VC; no randomized controlled trials were identified. The selected studies exhibited great heterogeneity in terms of PROMs use. Twenty-one different instruments assessed QoL. Most of the questionnaires were generic. Different issues (sexuality, lymphedema, body image, urinary and bowel function, vulva-specific symptoms) were reported as potentially important, but the results were not systematically collected. Only one VC-specific questionnaire was identified but did not allow for assessment and reporting on a scale level.CONCLUSIONS: Vulva cancer treatment is associated with considerable morbidity deteriorating QoL. To date, there is no validated PROM available that provides adequate coverage of VC-related issues. The study confirms the need for a VC-specific QoL instrument with sensitive scales that allows for broad cross-cultural application for use in clinical trials.",
keywords = "Female, Humans, Patient Reported Outcome Measures, Quality of Life, Vulvar Neoplasms/psychology",
author = "Froeding, {Ligita Paskeviciute} and Elfriede Greimel and Anne Lanceley and Anne Oberguggenberger and Claudia Schmalz and Radisic, {Vesna Bjelic} and Andy Nordin and Razvan Galalaei and Karin Kuljanic and Ingvild Vistad and Schnack, {Tine Henrichsen} and Jensen, {Pernille Tine} and {European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group}",
year = "2018",
month = may,
doi = "10.1097/IGC.0000000000001211",
language = "English",
volume = "28",
pages = "808--817",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "4",

}

RIS

TY - JOUR

T1 - Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients

T2 - A Systematic Literature Review

AU - Froeding, Ligita Paskeviciute

AU - Greimel, Elfriede

AU - Lanceley, Anne

AU - Oberguggenberger, Anne

AU - Schmalz, Claudia

AU - Radisic, Vesna Bjelic

AU - Nordin, Andy

AU - Galalaei, Razvan

AU - Kuljanic, Karin

AU - Vistad, Ingvild

AU - Schnack, Tine Henrichsen

AU - Jensen, Pernille Tine

AU - European Organization of Research Treatment of Cancer Quality of Life Group the Gynecological Cancer group

PY - 2018/5

Y1 - 2018/5

N2 - OBJECTIVES: Vulva cancer (VC) treatment carries a high risk of severe late effects that may have a negative impact on quality of life (QoL). Patient-reported outcome measures (PROMs) are increasingly used when evaluating disease- and treatment-specific effects. However, the adequacy of measures used to assess sequelae and QoL in VC remains unclear. The aims of the present study were to evaluate disease- and treatment-related effects as measured by PROMs in VC patients and to identify available VC-specific PROMs.METHODS/MATERIALS: A systematic literature search from 1990 to 2016 was performed. The inclusion criterion was report of disease- and treatment-related effects in VC patients using PROMs in the assessment. Methodological and reporting quality was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. This systematic review was performed as part of phase 1 of the development of a European Organisation for Research and Treatment of Cancer QoL questionnaire for VC patients.RESULTS: The search revealed 2299 relevant hits, with 11 articles extracted including a total of 535 women with VC; no randomized controlled trials were identified. The selected studies exhibited great heterogeneity in terms of PROMs use. Twenty-one different instruments assessed QoL. Most of the questionnaires were generic. Different issues (sexuality, lymphedema, body image, urinary and bowel function, vulva-specific symptoms) were reported as potentially important, but the results were not systematically collected. Only one VC-specific questionnaire was identified but did not allow for assessment and reporting on a scale level.CONCLUSIONS: Vulva cancer treatment is associated with considerable morbidity deteriorating QoL. To date, there is no validated PROM available that provides adequate coverage of VC-related issues. The study confirms the need for a VC-specific QoL instrument with sensitive scales that allows for broad cross-cultural application for use in clinical trials.

AB - OBJECTIVES: Vulva cancer (VC) treatment carries a high risk of severe late effects that may have a negative impact on quality of life (QoL). Patient-reported outcome measures (PROMs) are increasingly used when evaluating disease- and treatment-specific effects. However, the adequacy of measures used to assess sequelae and QoL in VC remains unclear. The aims of the present study were to evaluate disease- and treatment-related effects as measured by PROMs in VC patients and to identify available VC-specific PROMs.METHODS/MATERIALS: A systematic literature search from 1990 to 2016 was performed. The inclusion criterion was report of disease- and treatment-related effects in VC patients using PROMs in the assessment. Methodological and reporting quality was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. This systematic review was performed as part of phase 1 of the development of a European Organisation for Research and Treatment of Cancer QoL questionnaire for VC patients.RESULTS: The search revealed 2299 relevant hits, with 11 articles extracted including a total of 535 women with VC; no randomized controlled trials were identified. The selected studies exhibited great heterogeneity in terms of PROMs use. Twenty-one different instruments assessed QoL. Most of the questionnaires were generic. Different issues (sexuality, lymphedema, body image, urinary and bowel function, vulva-specific symptoms) were reported as potentially important, but the results were not systematically collected. Only one VC-specific questionnaire was identified but did not allow for assessment and reporting on a scale level.CONCLUSIONS: Vulva cancer treatment is associated with considerable morbidity deteriorating QoL. To date, there is no validated PROM available that provides adequate coverage of VC-related issues. The study confirms the need for a VC-specific QoL instrument with sensitive scales that allows for broad cross-cultural application for use in clinical trials.

KW - Female

KW - Humans

KW - Patient Reported Outcome Measures

KW - Quality of Life

KW - Vulvar Neoplasms/psychology

U2 - 10.1097/IGC.0000000000001211

DO - 10.1097/IGC.0000000000001211

M3 - Journal article

C2 - 29420364

VL - 28

SP - 808

EP - 817

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -